Market Cap
€51.7m
Last Updated
2021/03/07 18:31 UTC
Data Sources
Company Financials +
Executive Summary
Pierrel S.p.A. provides contract manufacturing services to the life science, biopharma, and pharmaceutical industries worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Outstanding track record with high growth potential.
Share Price & News
How has Pierrel's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PRL is more volatile than 90% of Italian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: PRL's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Italian stocks.
Market Performance
7 Day Return
-3.0%
PRL
-0.5%
IT Pharmaceuticals
1.3%
IT Market
1 Year Return
51.2%
PRL
-3.8%
IT Pharmaceuticals
6.6%
IT Market
Return vs Industry: PRL exceeded the Italian Pharmaceuticals industry which returned -3.8% over the past year.
Return vs Market: PRL exceeded the Italian Market which returned 6.7% over the past year.
Shareholder returns
| PRL | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.0% | -0.5% | 1.3% |
| 30 Day | 30.6% | -4.6% | 0.7% |
| 90 Day | 23.2% | -4.3% | 4.7% |
| 1 Year | 51.2%51.2% | -0.7%-3.8% | 9.8%6.6% |
| 3 Year | 20.4%10.2% | 28.2%13.7% | 4.1%-6.0% |
| 5 Year | -36.1%-41.5% | 33.2%11.6% | 10.0%-12.9% |
Long-Term Price Volatility Vs. Market
How volatile is Pierrel's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Calculating The Fair Value Of Pierrel S.p.A. (BIT:PRL)2 months ago | Simply Wall St
How Is Pierrel's (BIT:PRL) CEO Paid Relative To Peers?3 months ago | Simply Wall St
These 4 Measures Indicate That Pierrel (BIT:PRL) Is Using Debt ExtensivelyValuation
Is Pierrel undervalued compared to its fair value and its price relative to the market?
1.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PRL (€0.23) is trading below our estimate of fair value (€0.23)
Significantly Below Fair Value: PRL is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: PRL is good value based on its PE Ratio (17.4x) compared to the XE Pharmaceuticals industry average (23.7x).
PE vs Market: PRL is good value based on its PE Ratio (17.4x) compared to the Italian market (21x).
Price to Earnings Growth Ratio
PEG Ratio: PRL is good value based on its PEG Ratio (0.4x)
Price to Book Ratio
PB vs Industry: PRL is overvalued based on its PB Ratio (3.6x) compared to the XE Pharmaceuticals industry average (3.3x).
Next Steps
Future Growth
How is Pierrel forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
39.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRL's forecast earnings growth (39.3% per year) is above the savings rate (1.9%).
Earnings vs Market: PRL's earnings (39.3% per year) are forecast to grow faster than the Italian market (22% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PRL's revenue (27% per year) is forecast to grow faster than the Italian market (4.7% per year).
High Growth Revenue: PRL's revenue (27% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PRL's Return on Equity is forecast to be low in 3 years time (20%).
Next Steps
Past Performance
How has Pierrel performed over the past 5 years?
24.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRL has high quality earnings.
Growing Profit Margin: PRL's current net profit margins (15%) are higher than last year (4%).
Past Earnings Growth Analysis
Earnings Trend: PRL has become profitable over the past 5 years, growing earnings by 24.6% per year.
Accelerating Growth: PRL's earnings growth over the past year (242.5%) exceeds its 5-year average (24.6% per year).
Earnings vs Industry: PRL earnings growth over the past year (242.5%) exceeded the Pharmaceuticals industry 11.2%.
Return on Equity
High ROE: PRL's Return on Equity (20.8%) is considered high.
Next Steps
Financial Health
How is Pierrel's financial position?
Financial Position Analysis
Short Term Liabilities: PRL's short term assets (€10.2M) exceed its short term liabilities (€8.4M).
Long Term Liabilities: PRL's short term assets (€10.2M) do not cover its long term liabilities (€10.4M).
Debt to Equity History and Analysis
Debt Level: PRL's debt to equity ratio (78.7%) is considered high.
Reducing Debt: PRL's debt to equity ratio has reduced from 699.5% to 78.7% over the past 5 years.
Debt Coverage: PRL's debt is well covered by operating cash flow (36.8%).
Interest Coverage: PRL earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Pierrel current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PRL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PRL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PRL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PRL's dividend in 3 years as they are not forecast to pay a notable one for the Italian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
€527k
CEO Compensation
CEO
Fulvio Citaredo (58 yo)
no data
Tenure
€527,251
Compensation
Dr. Fulvio Citaredo serves as the Chief Executive Officer and Director of Pierrel S.p.A. since 2020 and serves as General Manager since October 2020. Dr. Citaredo served as its Corporate General Manager of...
CEO Compensation Analysis
Compensation vs Market: Fulvio's total compensation ($USD628.13K) is above average for companies of similar size in the Italian market ($USD372.98K).
Compensation vs Earnings: Fulvio's compensation has increased by more than 20% in the past year.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Pierrel S.p.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Pierrel S.p.A.
- Ticker: PRL
- Exchange: BIT
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €51.727m
- Shares outstanding: 228.88m
- Website: https://www.pierrelgroup.com
Location
- Pierrel S.p.A.
- s.s. Appia 7 bis 46/48
- Capua
- Caserta
- 81043
- Italy
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PRL | BIT (Borsa Italiana) | Yes | Common Stock | IT | EUR | May 2006 |
| 2FJ | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 2006 |
| PRLM | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Common Stock | GB | EUR | May 2006 |
Biography
Pierrel S.p.A. provides contract manufacturing services to the life science, biopharma, and pharmaceutical industries worldwide. The company is involved in the development of various types of drugs, such a...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/07 18:31 |
| End of Day Share Price | 2021/03/05 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.